This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of The Spanner Prostatic Stent (SRS Medical) for treatment of male bladder outlet obstruction (BOO) following transurethral treatment of the prostate.
Publications
Hayes Publications are available through the Hayes Knowledge Center, a portal to world-class research and unbiased analyses on the clinical, financial, and risk impacts of emerging, controversial, and disruptive healthcare technologies.Every Hayes publication is developed by multidisciplinary teams of clinicians and scientists using rigorous methods grounded in internally recognized standards for systematic review and Health Technology Assessment. Learn more about these evidence resources and see sample titles below.
See below for some of our recent publications.
Remestemcel-L (Mesoblast Ltd.) for Acute Graft-Versus-Host Disease
Remestemcel-L is an investigational allogeneic liquid cell suspension of ex-vivo cultured adult human mesenchymal stem cells derived from healthy donor bone marrow proposed for the treatment of pediatric patients with acute graft-versus-host-disease (aGVHD) refractory to standard first-line steroid therapy.
Sotatercept-csrk (Winrevair; Merck & Co. Inc.) for Pulmonary Arterial Hypertension
Sotatercept-csrk (Winrevair; Merck &Co. Inc.) is an activin signaling inhibitor indicated for the treatment of adults with World Health Organization (WHO) Group 1 pulmonary arterial hypertension to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening events.
The Spanner Prostatic Stent (SRS Medical) for Primary Treatment of Male Bladder Outlet Obstruction
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of The Spanner Prostatic Stent (SRS Medical) for primary treatment of male bladder outlet obstruction for urinary function, symptom relief, and quality of life improvement.
Minimally Invasive Posterior Sacroiliac Joint Fusion Using a Bone Allograft for Management of Sacroiliac Joint Pain
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of minimally invasive posterior sacroiliac joint (SIJ) fusion using engineered bone allografts placed within the SIJ for management of chronic SIJ pain.
Atidarsagene Autotemcel (Lenmeldy; Orchard Therapeutics) for Metachromatic Leukodystrophy
Atidarsagene autotemcel (Lenmeldy; Orchard Therapeutics) is an autologous hematopoietic stem cell-based gene therapy indicated for the treatment of children with presymptomatic late infantile, presymptomatic early juvenile, or early symptomatic early juvenile metachromatic leukodystrophy (MLD).
Prolastin-C (Grifols Therapeutics Inc.) Compared With Other Augmentation Therapies for Management of Patients With Alpha-1 Antitrypsin Deficiency and Lung Disease
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of alpha-1 antitrypsin (AAT) augmentation therapy with Prolastin or Prolastin-C over other alpha-1 proteinase inhibitors (A1PIs), for management of lung disease in patients with AAT deficiency (AATD).
Vowst (Fecal Microbiota Spores, Live-brpk; Seres Therapeutics Inc.) for Prevention of Recurrent Clostridioides Difficile Infection
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of Vowst (fecal microbiota spores, live-brpk; formerly SER-109) for prevention of recurrent Clostridioides difficile infection (rCDI).
Blarcamesine (Anavex 2-73; Anavex Life Sciences Corp.) for Alzheimer Disease
Blarcamesine (Anavex 2-73; Anavex Life Sciences Corp.) is an investigational oral small molecule sigma-1 receptor agonist for treatment of early Alzheimer disease.
Rebyota (Fecal Microbiota, Live-jslm) for Prevention of Recurrent Clostridioides Difficile Infection
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of Rebyota (fecal microbiota, live-jslm) for prevention of recurrent Clostridioides difficile infection (rCDI).